Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 83

1.

Targeted Peripheral Nerve-directed Onabotulinumtoxin A Injection for Effective Long-term Therapy for Migraine Headache.

Janis JE, Barker JC, Palettas M.

Plast Reconstr Surg Glob Open. 2017 Mar 28;5(3):e1270. doi: 10.1097/GOX.0000000000001270. eCollection 2017 Mar.

2.

Botulinum toxin in the management of chronic migraine: clinical evidence and experience.

Escher CM, Paracka L, Dressler D, Kollewe K.

Ther Adv Neurol Disord. 2017 Feb;10(2):127-135. doi: 10.1177/1756285616677005. Epub 2016 Nov 16. Review.

3.

Botulinum Toxin in Migraine Treatment.

Ilgaz Aydinlar E, Yalinay Dikmen P, Sağduyu Kocaman A.

Noro Psikiyatr Ars. 2013 Aug;50(Suppl 1):S36-S40. doi: 10.4274/npa.y7198. Epub 2013 Aug 1. Review.

4.

Prophylactic Treatment of Migraine.

Gürsoy AE, Ertaş M.

Noro Psikiyatr Ars. 2013 Aug;50(Suppl 1):S30-S35. doi: 10.4274/npa.y7199. Epub 2013 Aug 1. Review.

5.

The Face of Chronic Migraine Which Has Started to be Clarified.

Aydin Özemir Z, Baykan B.

Noro Psikiyatr Ars. 2013 Aug;50(Suppl 1):S21-S25. doi: 10.4274/npa.y7244. Epub 2013 Aug 1. Review.

6.

The therapeutic usage of botulinum toxin (Botox) in non-cosmetic head and neck conditions - An evidence based review.

Awan KH.

Saudi Pharm J. 2017 Jan;25(1):18-24. doi: 10.1016/j.jsps.2016.04.024. Epub 2016 Apr 30. Review.

7.

OnabotulinumtoxinA effectiveness on chronic migraine, negative emotional states and sleep quality: a single-center prospective cohort study.

Aydinlar EI, Dikmen PY, Kosak S, Kocaman AS.

J Headache Pain. 2017 Dec;18(1):23. doi: 10.1186/s10194-017-0723-4. Epub 2017 Feb 17.

8.

O034. Type of pain and onabotulinumtoxin-A in chronic migraine: four years of follow-up.

Cesaretti C, Molesti E, Lolli F, Amantini A, Lori S.

J Headache Pain. 2015 Dec;16(Suppl 1):A89. doi: 10.1186/1129-2377-16-S1-A89. No abstract available.

9.

P010. OnabotulinumtoxinA for treatment of chronic migraine: results after 1 year of treatment.

Rossi E, Lupi C, Benemei S, Geppetti P, De Cesaris F.

J Headache Pain. 2015 Dec;16(Suppl 1):A110. doi: 10.1186/1129-2377-16-S1-A110. No abstract available.

10.

P054. Chronic migraine and onabotulinumtoxinA: results from clinical practice.

Paolucci M, Altavilla R, Gambale G, Altamura C, Viticchi G, Bartolini M, Silvestrini M, Vernieri F.

J Headache Pain. 2015 Dec;16(Suppl 1):A117. doi: 10.1186/1129-2377-16-S1-A117. No abstract available.

11.

P045. OnabotulinumtoxinA: long term treatment for chronic migraine with medication overuse.

Guerzoni S, Cainazzo MM, Pini LA.

J Headache Pain. 2015 Dec;16(Suppl 1):A183. doi: 10.1186/1129-2377-16-S1-A183. No abstract available.

12.

Global Updates on the Future Directions of Neurotoxins and Fillers.

Downie JB, Patel A, Heningburg J.

Plast Reconstr Surg Glob Open. 2016 Dec 14;4(12 Suppl Anatomy and Safety in Cosmetic Medicine: Cosmetic Bootcamp):e1177. doi: 10.1097/GOX.0000000000001177. eCollection 2016 Dec.

13.

Real-life data in 115 chronic migraine patients treated with Onabotulinumtoxin A during more than one year.

Aicua-Rapun I, Martínez-Velasco E, Rojo A, Hernando A, Ruiz M, Carreres A, Porqueres E, Herrero S, Iglesias F, Guerrero AL.

J Headache Pain. 2016 Dec;17(1):112. Epub 2016 Dec 12.

14.

Prolonged Effect of OnabotulinumtoxinA on Chronic Migraine in 87 Koreans.

Byun JI, Sim JY, Kim M.

J Clin Neurol. 2017 Jan;13(1):98-100. doi: 10.3988/jcn.2017.13.1.98. Epub 2016 Nov 17. No abstract available.

15.

Brain Changes in Responders vs. Non-Responders in Chronic Migraine: Markers of Disease Reversal.

Hubbard CS, Becerra L, Smith JH, DeLange JM, Smith RM, Black DF, Welker KM, Burstein R, Cutrer FM, Borsook D.

Front Hum Neurosci. 2016 Oct 6;10:497. eCollection 2016.

16.

Onabotulinumtoxin-A treatment in Greek patients with chronic migraine.

Vikelis M, Argyriou AA, Dermitzakis EV, Spingos KC, Mitsikostas DD.

J Headache Pain. 2016 Dec;17(1):84. doi: 10.1186/s10194-016-0676-z. Epub 2016 Sep 17.

17.

Expression of messenger molecules and receptors in rat and human sphenopalatine ganglion indicating therapeutic targets.

Steinberg A, Frederiksen SD, Blixt FW, Warfvinge K, Edvinsson L.

J Headache Pain. 2016 Dec;17(1):78. doi: 10.1186/s10194-016-0664-3. Epub 2016 Sep 1. Erratum in: J Headache Pain. 2016 Dec;17(1):86.

18.

Botulinum toxin type A with or without needle electromyographic guidance in patients with cervical dystonia.

Wu C, Xue F, Chang W, Lian Y, Zheng Y, Xie N, Zhang L, Chen C.

Springerplus. 2016 Aug 8;5(1):1292. doi: 10.1186/s40064-016-2967-x. eCollection 2016.

19.

Chronic Daily Headache and Medication Overuse Headache in First-Visit Headache Patients in Korea: A Multicenter Clinic-Based Study.

Cha MJ, Moon HS, Sohn JH, Kim BS, Song TJ, Kim JM, Park JW, Park KY, Kim SK, Kim BK, Cho SJ.

J Clin Neurol. 2016 Jul;12(3):316-22. doi: 10.3988/jcn.2016.12.3.316.

20.

Chronic migraine headache prevention with noninvasive vagus nerve stimulation: The EVENT study.

Silberstein SD, Calhoun AH, Lipton RB, Grosberg BM, Cady RK, Dorlas S, Simmons KA, Mullin C, Liebler EJ, Goadsby PJ, Saper JR; EVENT Study Group..

Neurology. 2016 Aug 2;87(5):529-38. doi: 10.1212/WNL.0000000000002918. Epub 2016 Jul 13.

Supplemental Content

Support Center